# Crinetics Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 4, 2026 | Crinetics Canonical URL: https://biopharmsignal.com/news/CRNX/crinetics-pharmaceuticals-to-report-second-quarter-2026-financial-results-on-aug-6cad0f8c Ticker: CRNX Company: Crinetics Pharmaceuticals Source: Crinetics Pharmaceuticals Published: 2026-06-30 21:53 EST Original Source URL: https://crinetics.com/press-releases/ ## Summary June 30, 2026 SAN DIEGO, June 30, 2026 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will... ## Article Body June 30, 2026 SAN DIEGO, June 30, 2026 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report second quarter 2026 financial results on Tuesday, August 4, 2026 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update. Conference Call & Webcast Tuesday, August 4 at 4:30 p.m. ET Domestic: 1 833-461-5787 International: 1 585-542-9983 Meeting ID: 758613006 Webcast: Participants can use the dial-in numbers above OR access the live webcast via a direct link ( HERE ) or by visiting the Events section of the Crinetics website. To ensure a timely connection, it is recommended that participants connect at least 15 minutes prior to the scheduled start of the call. The webcast will be archived on the Investor Relations section of www.crinetics.com . About Crinetics Pharmaceuticals Crinetics Pharmaceuticals is a global pharmaceutical company committed to transforming the treatment of endocrine diseases and endocrine-related tumors through science rooted in patient needs. Crinetics is focused on discovering, developing, and commercializing novel therapies, with a core expertise in targeting G-protein coupled receptors (GPCRs) with small molecules that have specifically tailored pharmacology and properties. Crinetics’ first commercial product, PALSONIFY™ (paltusotine), is the first once-daily, oral treatment approved by the U.S. FDA and EMA for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option. Paltusotine is also in clinical development for carcinoid syndrome associated with neuroendocrine tumors. Crinetics’ deep pipeline of 10+ disclosed programs includes late-stage investigational candidate atumelnant, which is currently in development for congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome, and CRN09682, a nonpeptide drug conjugate candidate that is being developed to treat somatostatin receptor 2 (SST2) expressing neuroendocrine tumors and other SST2 expressing solid tumors. Additional discovery programs are focused on a variety of endocrine targets such as thyroid stimulating hormone (TSH), parathyroid hormone (PTH), somatostatin receptor 3 (SST3), growth hormone (GH), glucagon-like peptide-1 (GLP-1), and glucose-dependent insulinotropic polypeptide (GIP), as well as GPCR-targeted oncology indications. Investors: Gayathri Diwakar Head of Investor Relations gdiwakar@crinetics.com (858) 345-6340 Media: Natalie Badillo Head of Corporate Communications nbadillo@crinetics.com (858) 345-6075 Source: Crinetics Pharmaceuticals, Inc. DOWNLOAD PDF ## Recent Company News - 2026-07-09 15:43 EST — [Crinetics and Leading Patient Groups Launch ‘Everyday Advocacy’ Initiative to Empower People Across Endocrine Disease Communities | Crinetics](https://biopharmsignal.com/news/CRNX/crinetics-and-leading-patient-groups-launch-everyday-advocacy-initiative-to-empo-2503d5d7) — Source: Crinetics Pharmaceuticals - 2026-07-09 15:43 EST — [Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026 | Crinetics](https://biopharmsignal.com/news/CRNX/crinetics-presents-full-results-from-phase-2-trial-of-atumelnant-in-congenital-a-cc021e52) — Source: Crinetics Pharmaceuticals - 2026-07-06 20:10 EST — [Vertex to Acquire Crinetics Pharmaceuticals | Crinetics](https://biopharmsignal.com/news/CRNX/vertex-to-acquire-crinetics-pharmaceuticals-crinetics-29e39d07) — Source: Crinetics Pharmaceuticals - 2026-06-30 21:53 EST — [Crinetics Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 4, 2026 | Crinetics](https://biopharmsignal.com/news/CRNX/crinetics-pharmaceuticals-to-report-second-quarter-2026-financial-results-on-aug-6cad0f8c) — Source: Crinetics Pharmaceuticals - 2026-06-14 18:47 EST — [Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control | Crinetics](https://biopharmsignal.com/news/CRNX/crinetics-presents-long-term-data-at-endo-2026-confirming-palsonify-paltusotine--a16fc1b7) — Source: Crinetics Pharmaceuticals ## Related News - 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47) - 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640) - 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0) - 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f) - 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)